Childhood brain cancer remains one of the most challenging areas of modern medicine. Among the most aggressive forms are diffuse midline gliomas, including diffuse intrinsic pontine glioma (DIPG), which can be particularly difficult to treat. Dr. Michelle Monje, MD, PhD, a pediatric neuro-oncologist and researcher at Stanford University, has dedicated much of her career to understanding these devastating diseases and developing new approaches to treatment.
Dr. Monje’s work combines clinical medicine, neuroscience, and cancer biology. She is particularly interested in how brain activity influences tumor growth and how this relationship might be used to develop more effective therapies.
A Career Dedicated to Pediatric Neuro-Oncology
At Stanford Medicine, Dr. Monje leads research investigating the relationship between neural activity and brain tumors. Her work has helped advance the field of cancer neuroscience, which examines how interactions between nerve cells and cancer cells can influence disease progression.
Rather than viewing tumors as isolated groups of abnormal cells, her research explores how they interact with the surrounding brain environment. This perspective may reveal biological processes that conventional cancer treatments do not adequately address.
Her commitment to pediatric neuro-oncology is also shaped by the urgent need for better treatments for children diagnosed with aggressive brain tumors. Many of these cancers have limited treatment options, making scientific innovation especially important.
Investigating Innovative Immunotherapy
One of Dr. Monje’s most notable recent developments involves research into CAR T-cell therapy for diffuse midline gliomas. This approach modifies a patient’s immune cells so they can recognize and attack cancer cells.
In a clinical trial conducted with Stanford colleagues, researchers investigated CAR T cells targeting GD2, a molecule expressed by certain pediatric brain tumors. Results reported in 2025 showed promising signs of tumor response and improvements in neurological function and quality of life among some patients.
Although the findings are encouraging, this treatment remains investigational, and further research is needed to establish its safety, effectiveness, and long-term benefits.
Understanding How the Brain Influences Cancer
Dr. Monje’s team has also published important findings about communication between neurons and glioma cells. Research published in Nature in 2025 demonstrated that certain inhibitory neurons can form functional connections with diffuse midline glioma cells.
Additional research published in Cell in 2025 investigated how activity in specific brainstem circuits may promote tumor growth. These discoveries could help scientists identify new therapeutic targets and develop strategies that complement existing cancer treatments.
A Promising Direction for Future Medicine
Dr. Michelle Monje’s work illustrates how combining neuroscience with cancer research can generate new possibilities for treating difficult diseases. Her research program brings together laboratory discoveries, clinical trials, and collaboration across scientific disciplines.
While much work remains before experimental approaches become established treatments, her contributions are helping researchers better understand childhood brain cancer and investigate new therapeutic possibilities.
Through her dedication to pediatric patients and innovative research, Dr. Monje represents the important role physician-scientists play in advancing medicine and creating opportunities for future breakthroughs.
